TY - JOUR
T1 - Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia
T2 - Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
AU - Wierda, William G.
AU - Allan, John N.
AU - Siddiqi, Tanya
AU - Kipps, Thomas J.
AU - Opat, Stephen
AU - Tedeschi, Alessandra
AU - Badoux, Xavier C.
AU - Kuss, Bryone J.
AU - Jackson, Sharon
AU - Moreno, Carol
AU - Jacobs, Ryan M.D.
AU - Pagel, John M.
AU - Flinn, Ian
AU - Pak, Yvonne
AU - Zhou, Cathy
AU - Szafer-Glusman, Edith
AU - Ninomoto, Joi
AU - Dean, James P.
AU - James, Danelle F.
AU - Ghia, Paolo
AU - Tam, Constantine S.
N1 - Publisher Copyright:
© 2022 American Society of Clinical Oncology. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS Previously untreated CLL patients age, 70 years received three cycles of ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD cohort who met the stringent random assignment criteria for confirmed undetectable MRD (Confirmed uMRD) were randomly assigned 1:1 to double-blind placebo or ibrutinib; patients without Confirmed uMRD (uMRD Not Confirmed) were randomly assigned 1:1 to open-label ibrutinib or ibrutinib plus venetoclax. Primary end point was 1-year disease-free survival (DFS) rate with placebo versus ibrutinib in the Confirmed uMRD population. Secondary end points included response rates, uMRD, and safety. RESULTS One hundred sixty-four patients initiated three cycles of ibrutinib lead-in. After 12 cycles of ibrutinib plus venetoclax, best uMRD response rates were 75% (peripheral blood) and 68% (bone marrow). Patients with Confirmed uMRD were randomly assigned to receive placebo (n 5 43) or ibrutinib (n 5 43); patients with uMRD Not Confirmed were randomly assigned to ibrutinib (n 5 31) or ibrutinib plus venetoclax (n 5 32). Median followup was 31.3 months. One-year DFS rate was not significantly different between placebo (95%) and ibrutinib (100%; arm difference: 4.7% [95% CI, –1.6 to 10.9]; P 5 .15) in the Confirmed uMRD population. After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%) with high tumor lysis syndrome risk at baseline shifted to medium or low tumor lysis syndrome risk categories. Adverse events were most frequent during the first 6 months of ibrutinib plus venetoclax and generally decreased over time. CONCLUSION The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, once-daily, chemotherapy-free regimen in first-line CLL.
AB - PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS Previously untreated CLL patients age, 70 years received three cycles of ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD cohort who met the stringent random assignment criteria for confirmed undetectable MRD (Confirmed uMRD) were randomly assigned 1:1 to double-blind placebo or ibrutinib; patients without Confirmed uMRD (uMRD Not Confirmed) were randomly assigned 1:1 to open-label ibrutinib or ibrutinib plus venetoclax. Primary end point was 1-year disease-free survival (DFS) rate with placebo versus ibrutinib in the Confirmed uMRD population. Secondary end points included response rates, uMRD, and safety. RESULTS One hundred sixty-four patients initiated three cycles of ibrutinib lead-in. After 12 cycles of ibrutinib plus venetoclax, best uMRD response rates were 75% (peripheral blood) and 68% (bone marrow). Patients with Confirmed uMRD were randomly assigned to receive placebo (n 5 43) or ibrutinib (n 5 43); patients with uMRD Not Confirmed were randomly assigned to ibrutinib (n 5 31) or ibrutinib plus venetoclax (n 5 32). Median followup was 31.3 months. One-year DFS rate was not significantly different between placebo (95%) and ibrutinib (100%; arm difference: 4.7% [95% CI, –1.6 to 10.9]; P 5 .15) in the Confirmed uMRD population. After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%) with high tumor lysis syndrome risk at baseline shifted to medium or low tumor lysis syndrome risk categories. Adverse events were most frequent during the first 6 months of ibrutinib plus venetoclax and generally decreased over time. CONCLUSION The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, once-daily, chemotherapy-free regimen in first-line CLL.
UR - http://www.scopus.com/inward/record.url?scp=85121427097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121427097&partnerID=8YFLogxK
U2 - 10.1200/JCO.21.00807
DO - 10.1200/JCO.21.00807
M3 - Article
C2 - 34618601
AN - SCOPUS:85121427097
SN - 0732-183X
VL - 39
SP - 3853
EP - 3865
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 34
ER -